These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 35998514)

  • 1. Management of patients with early-stage triple-negative breast cancer following pembrolizumab-based neoadjuvant therapy: What are the evidences?
    Bonadio RC; Tarantino P; Testa L; Punie K; Pernas S; Barrios C; Curigliano G; Tolaney SM; Barroso-Sousa R
    Cancer Treat Rev; 2022 Nov; 110():102459. PubMed ID: 35998514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current usage of pembrolizumab in triple negative breast cancer (TNBC).
    O'Rourke H; Hart C; De Boer RH
    Expert Rev Anticancer Ther; 2024 May; 24(5):253-261. PubMed ID: 38594892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shifting Paradigms in TNBC Treatment: Emerging Alternatives to Capecitabine in the Post-Neoadjuvant Setting.
    Abahssain H; Souadka A; Alem R; Santoni M; Battelli N; Amela E; Lemaire A; Rodriguez J; Errihani H
    Curr Oncol; 2024 Jun; 31(7):3771-3782. PubMed ID: 39057150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. OptimICE-RD: sacituzumab govitecan + pembrolizumab vs pembrolizumab (± capecitabine) for residual triple-negative breast cancer.
    Tolaney SM; DeMichele A; Takano T; Rugo HS; Perou C; Lynce F; Parsons HA; Santa-Maria CA; Rocque GB; Yao W; Sun SW; Mocci S; Partridge AH; Carey LA
    Future Oncol; 2024; 20(31):2343-2355. PubMed ID: 38922307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted Therapies and the Evolving Standard of Care for Triple-Negative and Germline
    Desai NV; Tan AR
    JCO Precis Oncol; 2023 May; 7():e2200446. PubMed ID: 37163718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress in immune checkpoint inhibition in early-stage triple-negative breast cancer.
    Mohamed A; Kruse M; Tran J
    Expert Rev Anticancer Ther; 2023; 23(10):1071-1084. PubMed ID: 37747062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United States.
    Huang M; A Fasching P; Haiderali A; Xue W; Yang C; Pan W; Zhou ZY; Hu P; Chaudhuri M; Le Bailly De Tilleghem C; Cappoen N; O'Shaughnessy J
    Adv Ther; 2023 Mar; 40(3):1153-1170. PubMed ID: 36648737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
    Schmid P; Cortes J; Dent R; Pusztai L; McArthur H; Kümmel S; Bergh J; Denkert C; Park YH; Hui R; Harbeck N; Takahashi M; Untch M; Fasching PA; Cardoso F; Andersen J; Patt D; Danso M; Ferreira M; Mouret-Reynier MA; Im SA; Ahn JH; Gion M; Baron-Hay S; Boileau JF; Ding Y; Tryfonidis K; Aktan G; Karantza V; O'Shaughnessy J;
    N Engl J Med; 2022 Feb; 386(6):556-567. PubMed ID: 35139274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal adjuvant treatment strategies for TNBC patients with residual disease after neoadjuvant treatment.
    Guven DC; Yildirim HC; Kus F; Erul E; Kertmen N; Dizdar O; Aksoy S
    Expert Rev Anticancer Ther; 2023; 23(10):1049-1059. PubMed ID: 37224429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atezolizumab and pembrolizumab in triple-negative breast cancer: a meta-analysis.
    Latif F; Bint Abdul Jabbar H; Malik H; Sadaf H; Sarfraz A; Sarfraz Z; Cherrez-Ojeda I
    Expert Rev Anticancer Ther; 2022 Feb; 22(2):229-235. PubMed ID: 34949142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy in Early-Stage Triple-Negative Breast Cancer: Where Are We Now and Where Are We Headed?
    Dixon-Douglas J; Loi S
    Curr Treat Options Oncol; 2023 Aug; 24(8):1004-1020. PubMed ID: 37222922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDA Approval Summary: Pembrolizumab for Neoadjuvant and Adjuvant Treatment of Patients with High-Risk Early-Stage Triple-Negative Breast Cancer.
    Shah M; Osgood CL; Amatya AK; Fiero MH; Pierce WF; Nair A; Herz J; Robertson KJ; Mixter BD; Tang S; Pazdur R; Beaver JA; Amiri-Kordestani L
    Clin Cancer Res; 2022 Dec; 28(24):5249-5253. PubMed ID: 35925043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study.
    Schmid P; Salgado R; Park YH; Muñoz-Couselo E; Kim SB; Sohn J; Im SA; Foukakis T; Kuemmel S; Dent R; Yin L; Wang A; Tryfonidis K; Karantza V; Cortés J; Loi S
    Ann Oncol; 2020 May; 31(5):569-581. PubMed ID: 32278621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.
    Winer EP; Lipatov O; Im SA; Goncalves A; Muñoz-Couselo E; Lee KS; Schmid P; Tamura K; Testa L; Witzel I; Ohtani S; Turner N; Zambelli S; Harbeck N; Andre F; Dent R; Zhou X; Karantza V; Mejia J; Cortes J;
    Lancet Oncol; 2021 Apr; 22(4):499-511. PubMed ID: 33676601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addressing Residual Disease in HER2-Positive and Triple-Negative Breast Cancer: What Is Next?
    Schlam I; Dower J; Lynce F
    Curr Oncol Rep; 2024 Apr; 26(4):336-345. PubMed ID: 38393609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pembrolizumab for Early Triple-Negative Breast Cancer.
    Schmid P; Cortes J; Pusztai L; McArthur H; Kümmel S; Bergh J; Denkert C; Park YH; Hui R; Harbeck N; Takahashi M; Foukakis T; Fasching PA; Cardoso F; Untch M; Jia L; Karantza V; Zhao J; Aktan G; Dent R; O'Shaughnessy J;
    N Engl J Med; 2020 Feb; 382(9):810-821. PubMed ID: 32101663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy?
    Dülgar Ö; Öven BB; Atcı MM; Arıkan R; Ay S; Ayhan M; Selvi O; Ozyukseler DT; Bayram E; Özcan E; Yasin Aİ; Gümüş M
    Expert Rev Anticancer Ther; 2022 Jul; 22(7):773-780. PubMed ID: 35543015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy for Early-Stage Triple Negative Breast Cancer: Is Earlier Better?
    Song F; Tarantino P; Garrido-Castro A; Lynce F; Tolaney SM; Schlam I
    Curr Oncol Rep; 2024 Jan; 26(1):21-33. PubMed ID: 38198112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131.
    Mayer IA; Zhao F; Arteaga CL; Symmans WF; Park BH; Burnette BL; Tevaarwerk AJ; Garcia SF; Smith KL; Makower DF; Block M; Morley KA; Jani CR; Mescher C; Dewani SJ; Tawfik B; Flaum LE; Mayer EL; Sikov WM; Rodler ET; Wagner LI; DeMichele AM; Sparano JA; Wolff AC; Miller KD
    J Clin Oncol; 2021 Aug; 39(23):2539-2551. PubMed ID: 34092112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneity of Residual Disease After Neoadjuvant Systemic Therapy in Breast Cancer: A Review.
    Tarantino P; Hortobagyi G; Tolaney SM; Mittendorf EA
    JAMA Oncol; 2024 Nov; 10(11):1578-1584. PubMed ID: 39264638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.